10-15-13 8:45 AM EDT | Email Article

Johnson & Johnson's (JNJ) third-quarter earnings edged up slightly as the health-products giant again was buoyed by new prescription drugs as it seeks to replace older blockbusters that have lost patent protection.

For the year, J&J raised its per-share earnings estimate to $5.44 to $5.49, from its previous estimate of $5.40 to $5.45.

The New Brunswick, N.J., health-products maker has been trying to recover from a long string of recalls for a variety of products including Tylenol, which have cost it hundreds of millions of dollars in sales and prompted close government oversight of some factories.

Like other major drug makers, J&J has been realigning its portfolio as it aims to fill its product development pipeline and boost its profit. In July, J&J reached a $185 million deal to sell its feminine hygiene brands in the U.S., Canada and the Caribbean to Energizer Holdings Inc. (ENR). More recently The Wall Street Journal reported that it was looking for a buyer for its Ortho Clinical Diagnostics blood-testing division, which could be valued at about $5 billion.

J&J's pharmaceuticals business has been benefiting from the introduction of new drugs such as prostate-cancer treatment Zytiga and bloodthinner Xarelto. In the latest quarter, pharmaceutical sales were up 9.9% to $7 billion.

J&J reported a profit of $2.98 billion, up from $2.96 billion a year earlier. Per-share earnings slipped by one cent to $1.04. Excluding charges related to last year's acquisition of trauma-device maker Synthes, litigation-related impacts and other items, adjusted earnings were up at $1.36 from $1.25. Revenue increased 3.1% to $17.6 billion. Excluding currency impacts, the growth was 4.7%.

Analysts polled by Thomson Reuters recently expected per-share earnings of $1.32 and revenue of $17.44 billion.

Shares were up 1.7% at $91.30 in recent premarket trading. Through the close, the stock is up 28% this year.

Write to Tess Stynes at tess.stynes@wsj.com

 

Subscribe to WSJ: http://online.wsj.com?mod=djnwires


(END) Dow Jones Newswires

October 15, 2013 08:45 ET (12:45 GMT)

Copyright (c) 2013 Dow Jones & Company, Inc.
Add a Comment

News   More...

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Content Partners
Morningstar - 2013/10/15 - J&J Profit Edges Up
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Author |  Collection |  Interest |  Popularity

Previous: J&J in $4 Billion Settlement Talks  |  Next: J&J sells Ortho-Clinical Diagnostics for $4 bln